To minimize immunological tolerance and tumor cell growth, ICIs interfere with the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) signaling pathway and inhibit the cytotoxic T lymphocyte-associated antigen-4 [15]. Here, PDCD1 is linked to neoplasm.